Multifunctional Small Molecules as Potential Anti-Alzheimer’s Disease Agents

Author:

Bargagna BeatriceORCID,Ciccone LidiaORCID,Nencetti SusannaORCID,Santos M. AméliaORCID,Chaves SílviaORCID,Camodeca Caterina,Orlandini Elisabetta

Abstract

Alzheimer’s disease (AD) is a severe multifactorial neurodegenerative disorder characterized by a progressive loss of neurons in the brain. Despite research efforts, the pathogenesis and mechanism of AD progression are not yet completely understood. There are only a few symptomatic drugs approved for the treatment of AD. The multifactorial character of AD suggests that it is important to develop molecules able to target the numerous pathological mechanisms associated with the disease. Thus, in the context of the worldwide recognized interest of multifunctional ligand therapy, we report herein the synthesis, characterization, physicochemical and biological evaluation of a set of five (1a–e) new ferulic acid-based hybrid compounds, namely feroyl-benzyloxyamidic derivatives enclosing different substituent groups, as potential anti-Alzheimer’s disease agents. These hybrids can keep both the radical scavenging activity and metal chelation capacity of the naturally occurring ferulic acid scaffold, presenting also good/mild capacity for inhibition of self-Aβ aggregation and fairly good inhibition of Cu-induced Aβ aggregation. The predicted pharmacokinetic properties point towards good absorption, comparable to known oral drugs.

Funder

Ministero dell’Istruzione, dell’Università e della Ricerca

Fundação para a Ciência e a Tecnologia

European Cooperation in Science and Technology

Publisher

MDPI AG

Subject

Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science

Reference53 articles.

1. 2019 Alzheimer's disease facts and figures

2. Alzheimer’s Disease International World Alzheimer Report 2019https://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf

3. Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease

4. Frontiers in Clinical Drug Research—Alzheimer Disordershttps://www.eurekaselect.com/170302/volume/8

5. FDA approves first drug therapy for Alzheimer's in 18 years

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3